Xenon Pharmaceuticals Inc. (XENE)
| Previous Close | 42.49 |
| Open | 40.76 |
| Bid | 39.80 x 100 |
| Ask | 39.98 x 100 |
| Day's Range | 38.60 - 42.56 |
| 52 Week Range | 27.99 - 50.99 |
| Volume | |
| Avg. Volume | 354,450 |
| Market Cap | 3.01B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.73 |
| Earnings Date | Aug 07, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 58.10 |
ZacksXenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus
Xenon (XENE) reports better-than-expected first-quarter 2024 earnings. Its development programs for azetukalner in epilepsy and MDD are progressing well.
GlobeNewswireXenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase 3 program on track to initiate in the second half of the year Azetukalner now the international nonproprietary name (INN) and United States adopted name (USAN) for XEN1101 Conference call at 4:30 pm ET today VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nas
- GlobeNewswire
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV. Fireside Chat Presentation Details:Date:Wednesday, May 15, 2024Time:3:40 pm Pacific Time (6:40 pm Eastern Time)Webcast:Register herePresenters:Ian Mortimer, President and Chief Executive OfficerSherry A
